HEOR & HTA Support
Demonstrating the clinical and economic value of a medicine or healthcare technology has become increasingly important, and often essential. As HTA methodologies evolve to address affordability challenges, economic analysis and outcomes research must also adapt to meet the expectations of payers, regulators, and health systems.
Budget impact and cost-effectiveness analyses have traditionally supported national reimbursement decisions, but they are now equally relevant to regional and local stakeholders, including hospital pharmacists and integrated care systems. Early modelling can help fine-tune market access strategy and potential price points, whereas systematic and targeted literature reviews can inform gap analysis, evidence generation planning and execution, clinical trial design, and real-world evidence strategies that resonate with decision-makers.
Navigating HTA processes and achieving reimbursement requires more than robust data. It demands a clear understanding of how value is perceived and assessed across markets. Solaris supports clients through every stage of this journey, from early strategy development and evidence planning to submission and stakeholder engagement. Our global expertise enables us to identify the most effective pathways for demonstrating clinical and economic value, optimising submissions, and securing positive reimbursement outcomes.
We offer end-to-end support to help you anticipate payer needs, optimise evidence packages, and position your product for successful access and reimbursement.
Preparing for reimbursement
Evidence Generation Planning
Early planning is always a good idea. Our team can build evidence development programmes early in phase 2, ensuring phase 3 trials meet HTA agencies’ needs. We can also lead you through the scientific advice processes offered by regulators and HTA organisations.
Testing
Testing payer reactions to a target product profile, data or price point through primary research can determine whether a particular study is necessary to support access, for instance, or what evidence is needed to support sales volume assumptions.
Value Demonstration & Communication
We use modelling to identify pricing opportunities, or to quantify clinical trial endpoint thresholds for a product to be cost-effective. Closer to launch, we build budget impact and cost-effectiveness models and link them to interactive communication tools.
We can identify the most appropriate solutions for your product and the challenges you face. We validate these key assumptions with clinicians and payer advisors, while working alongside the functions in your organisation.
Literature reviews
Our experienced team apply the most appropriate methodology to ensure scientific rigour while supporting your research objectives, whether that is support with a targeted review for early value communication materials or a systematic literature review to support economic models or reimbursement dossiers for HTA reviews.
HTA Monitoring
Staying informed about global HTA decisions in your therapy areas of interest is now simpler than ever with RJW's customized monthly insight reports. We provide expert guidance on emerging trends and key decisions to support the development of your own HTA strategy.
How we stand out
We are flexible and pragmatic - we adapt our approach to your situation and needs. Our goal is to provide you with an actionable analysis to maximise your product's price and market access potential.
Our services
Developing market access and HTA strategies
HTA in a box - essential resources for developing your optimal HTA strategy, culminating in an engaging full-day workshop
Regulatory and HTA scientific advice
Evidence generation planning and gap analysis
Systematic and targeted literature reviews
Analogue analysis
Early economic modelling, and cost effectiveness and budget impact models
Payer and healthcare professional testing and primary research
